Selected article for: "ability target and address need"
Author: Scholtz, Alexis; Ramoji, Anuradha; Silge, Anja; Jansson, Jakob R.; de Moura, Ian G.; Popp, Jürgen; Sram, Jakub P.; Armani, Andrea M.
Title: COVID-19 Diagnostics: Past, Present, and Future
  • Cord-id: j9vhy7yz
  • Document date: 2021_9_15
    • ID: j9vhy7yz
    Snippet: [Image: see text] In winter of 2020, SARS-CoV-2 emerged as a global threat, impacting not only health but also financial and political stability. To address the societal need for monitoring the spread of SARS-CoV-2, many existing diagnostic technologies were quickly adapted to detect SARS-CoV-2 RNA and antigens as well as the immune response, and new testing strategies were developed to accelerate time-to-decision. In parallel, the infusion of research support accelerated the development of new
    Document: [Image: see text] In winter of 2020, SARS-CoV-2 emerged as a global threat, impacting not only health but also financial and political stability. To address the societal need for monitoring the spread of SARS-CoV-2, many existing diagnostic technologies were quickly adapted to detect SARS-CoV-2 RNA and antigens as well as the immune response, and new testing strategies were developed to accelerate time-to-decision. In parallel, the infusion of research support accelerated the development of new spectroscopic methods. While these methods have significantly reduced the impact of SARS-CoV-2 on society when coupled with behavioral changes, they also lay the groundwork for a new generation of platform technologies. With several epidemics on the horizon, such as the rise of antibiotic-resistant bacteria, the ability to quickly pivot the target pathogen of this diagnostic toolset will continue to have an impact.

    Search related documents:
    Co phrase search for related documents
    • absence presence and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acquire difficult and machine learning: 1, 2
    • active infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and machine learning: 1, 2
    • active infection diagnose and machine learning: 1
    • active research and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active research area and machine learning: 1, 2, 3, 4, 5
    • acute infection and low threshold: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional incentive and machine learning: 1
    • lod detection and machine learning: 1, 2, 3
    • lod detection limit and machine learning: 1, 2, 3
    • low sensitivity and lung tissue: 1, 2
    • low sensitivity and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • low specificity and lung tissue: 1
    • low specificity and machine learning: 1, 2, 3, 4, 5, 6, 7, 8
    • low specificity high sensitivity and lung tissue: 1
    • low specificity high sensitivity and machine learning: 1, 2